InvestorsHub Logo
Post# of 252302
Next 10
Followers 11
Posts 878
Boards Moderated 0
Alias Born 10/27/2003

Re: None

Friday, 05/17/2024 2:01:16 PM

Friday, May 17, 2024 2:01:16 PM

Post# of 252302
Amgen; Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC).

Amgen is proud to deliver the first targeted immunotherapy to this patient population.

🔗 Press release: https://amgen.ly/3X35AWL

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.